

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052922 A2

- (51) International Patent Classification⁷: C07K 7/00
- (21) International Application Number: PCT/GB2003/005323
- (22) International Filing Date: 5 December 2003 (05.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/431,620 6 December 2002 (06.12.2002) US
- (71) Applicant (for all designated States except US): SINGAPORE GENERAL HOSPITAL PTE LTD. [SG/SG]; 11 Third Hospital Avenue, #07-00, SNEC Building, 168751 Singapore (SG).
- (71) Applicant (for MN only): DENISON, Christopher, M [GB/GB]; C/o. Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): XIAO, Zhi-Cheng [CA/SG]; 173 Chin Swee Road, #32-02, 169878 Singapore (SG).
- (74) Agents: DENISON, Christopher, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: CENTRAL NERVOUS SYSTEM DAMAGE

AMORCES PCR

MAG1: 5- CG GGA TCC ATG ATA TTC CTT ACC ACC CT.
BamH I Met

MAG2: 5- TCC C CGC GGC TCG GTG TGC TCC CTG GAA
Sac II

TNR1: 5-TCC CC GCG GCA TGT CCA TGT GCC AGT TCA
Sac II

TNR2: 5- TT GC GGC CGC TGG AGG GGC AAC TGC TGA
Not I

NogoN1: 5-TT GCG GCC GCA ATG GAA GAC CTG GAC CAG TCT
Not I

NogoN2: 5-AAA C TGC AGC CAC TGA GCC CGA GGA GCC CCT
Pst I

Nogo66-1: 5-AAA CT GCA GCA AGG ATA TAC AAG GGT GT
Pst I

Nogo66-2: 5- GC TCT AGA TCA CTT CAG AGA ATC AAC TA
Xba I ***

CONSTRUCTION OBTENUE A PARTIR DE PRODUITS PCR RELIES SEQUENTIELLEMENT

5'-GGA TCC (MAG) GCC GCG GCA (TNR) GCG GCC GCA (NogoN) GCT GCA GCA
BamH I Sac II Not I Pst I

(Nogo66) TGA TCT AGA-3'
Xba I

(57) Abstract: The application provides peptides that interact with the inhibitory domains of the myelin proteins Nogo, TNF and MAG. These may be used in the treatment for CNS damage, and for the development of further treatments. Also provided are methods and materials for immunizing subjects against the inhibitory domains of the myelin proteins, for the treatment for CNS damage.